

Pharmacy Formulary Updates for March 2020

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status March 2020:

| Drug Name | Tufts Health Public Plan Formulary |
|--------------------------------------|---|
| | Tufts Health Together ACO - MA |
| Divigel 1.25 mg/1.25 gram gel | \$3.65 |
| Nayzilam nasal solution | \$3.65; PA (PA applies to members 0 through 11 years of age; No PA required for members 12 years of age and older) |
| Vitamin E 180 mg capsule | NC |
| Complete Omega capsule | NC |
| Acetaminophen 325 mg chewable tablet | NC |
| Tramadol 100 mg tablet | NC;QL |
| Brukinsa capsule | \$3.65;PA |
| Givlaari subcutaneous solution | MB/RX;PA |
| Reblozyl subcutaneous solution | MB/RX;PA |
| Xenleta tablet | \$3.65 |
| Xenleta intravenous solution | MB/RX |
| Jatenzo capsule | \$3.65;PA;QL |
| Consensi tablet | NC |
| Absorica LD capsule | \$3.65;PA |
| Asmanex HFA 50 mcg inhaler | \$3.65 |
| Dulera HFA 50 mcg-5 mcg inhaler | \$3.65;PA |
| Azeschew chewable tablet | NC |

Key

- MB:** Medical Benefit
- NC:** Not covered
- NTM:** New-to-market
- PA:** Prior Authorization
- MB/RX:** Drug can be dispensed through Medical Benefit or Prescription Benefit
- QL:** Quantity Limitation
- SP:** Specialty Pharmacy - provided through CVS/specialty
- ST:** Step Therapy